Genenta Science

Industry: Healthcare, Medical Technologies

Reference Market: US, IT

Inflow: MI2020 NewYork2019, Portfolio

Total capital raised so far: $87M


Key person infos

Nome Cognome: Pierluigi Paracchi

Ruolo: Founder & CEO


Cure patients affected by cancer.

Temferon™ is able to break the tumor immune-tolerance by reprogramming the tumor immune microenvironment.

Genenta develops an ex-vivo immuno-gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to target immunomodulatory molecules to tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEMs). The targeted expression of the immunomodulatory molecules in TEMs is achieved combining a transcriptional and a microRNA-mediated post-transcriptional control. Thanks to these mechanisms, TEMs become capable to express the immunomodulatory molecule (Interferon-alpha – IFN-a) into the tumor microenvironment. TEMs are spontaneously and actively recruited by developing tumors to sustain their growth and thanks to the immune-gene transfer, TEMs become the tool for the local delivery of the immunomodulatory molecule. The local IFN-a release triggers both direct and indirect anti-tumor effects including an immune-response. In contrast to antigen-restricted Chimeric Antigen Receptor T cells (CAR-T), Temferon™ may reach also solid tumors and exerts its immune-modulatory functions triggering a long-lasting immune response towards multiple antigens.